The Hospitalist Perspective on Treatment of Community–Acquired Bacterial Pneumonia

References

• . Bonafede MM, Suaya JA, Wilson KL, Mannino DM, Polsky D. Incidence and cost of CAP in a large working-age population. Am J Managed Care. 2012;18(7):380–387
   PubMed Web of Science ®Google Scholar
• . Hall MJ, DeFrances CJ, Williams SN, Golonsinskiy MS, Schwartzman A. National Hospital Discharge Survey: 2007 Summary. National Health Statistics Reports. 2010;29:1–24. Hyattsville, MD: Centers for Disease Control and Prevention
   Google Scholar
• . Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2012, with chartbook on trends in the health of Americans. http://www.cdc.gov/nchs/data/hus/hus06.pdf. Accessed June 26, 2013
   Google Scholar
• . Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY antimicrobial surveillance program (1998–2011). Diagn Microbiol Infect Dis. 2013;75(1):107–109
   PubMed Web of Science ®Google Scholar
• . Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008–2010). Clin Infect Dis. 2012;55( suppl 3):S206–S214
   Google Scholar
• . Mandell LA, Wunderink RG, Anzueto A, ; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44( suppl 2):S27–S72
   PubMed Web of Science ®Google Scholar
• . Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009;30(2):210–238
   PubMed Web of Science ®Google Scholar
• . Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011;52( Suppl 4):S296–S304
   PubMed Web of Science ®Google Scholar
• . File TM Jr, Low DE, Eckburg PE, ; FOCUS 1 Investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66( suppl 3):iii19–iii32
   PubMed Web of Science ®Google Scholar
• . Moran GJ, Krishnadasan A, Gorwitz RJ, ; EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54(8):1126–1133
   PubMed Web of Science ®Google Scholar
• . Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16(5):e321–e331
   PubMed Web of Science ®Google Scholar
• . Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am. 2013;27(1):177–188
   PubMed Web of Science ®Google Scholar
• . Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of cuture-positive pneumonia. Chest. 2005;128(6):3854–3862
   PubMed Web of Science ®Google Scholar
• . Chalmers JD, Taylor JK, Singanayagam A, . Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53(2):107–113
   PubMed Web of Science ®Google Scholar
• . Pavia AT. What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for infuenza and other viral causes of community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1):157–175
   PubMed Web of Science ®Google Scholar
• . Cillóniz C, Ewig S, Polverino E, . Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340–346
   PubMed Web of Science ®Google Scholar
• . Hash RB, Stephens JL, Laurens MB, Vogel RL. The relationship between volume status, hydration, and radiographic findings in the diagnosis of community-acquired pneumonia. J Fam Pract. 2000;49(9):833–837
   PubMed Web of Science ®Google Scholar
• . Ressig A, Gramegna A, Aliberti S. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. Eur J Intern Med. 2012;23(5):391–397
   PubMed Web of Science ®Google Scholar
• . Ressig A, Copetti R, Mathis G, . Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study. Chest. 2012;142(4):965–972
   PubMedGoogle Scholar
• . Alves dos Santos JW, Torres A, Michel GT, . Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med. 2004;98(6):488–494
   PubMed Web of Science ®Google Scholar
• . Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am. 2001;85(6):1511–1530
   PubMed Web of Science ®Google Scholar
• . Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011;171(13):1193–1198
   PubMedGoogle Scholar
• . File TM Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med. 2011;32(3):417–430
   PubMed Web of Science ®Google Scholar
• . BioFire Diagnostics, Inc. FilmArray Respiratory Panel. http://www.biofiredx.com/pdfs/FilmArray/InfoSheet,%20FilmArray%20Respiratory%20Panel-0229.pdf. Accessed September 18, 2013
   Google Scholar
• . illumigene [package insert]. Cincinnati, OH: Meridian Bioscience, Inc.; 2013
   Google Scholar
• . Upadhyay S, Niederman MS. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am. 2013;27(1):19–31
   PubMed Web of Science ®Google Scholar
• . Schuetz P, Christ-Crain M, Thomann R, ; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066
   PubMed Web of Science ®Google Scholar
• . van Vugt SF, Broekhuizen BDL, Lammens C, ; Grace Consortium. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013;346:f2450
   PubMed Web of Science ®Google Scholar
• . Sinclair A, Xie X, Dendukuri N. The clinical effectiveness and cost of a pneumococcal urine antigen immunochromatographic test (BinaxNOW Streptococcus pneumoniae) in the diagnosis of community acquired Streptococcus pneumoniae pneumonia in patients admitted to hospital. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2012. Report no. 57. 58 p. https://secureweb.mcgill.ca/tau/sites/mcgill.ca.tau/files/muhc_tau_2011_57_binaxnow.pdf. Accessed October 28, 2013
   Google Scholar
• . Marti C, Garin N, Grosgurin O, . Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141
   PubMed Web of Science ®Google Scholar
• . Pereira JM, Paiva JA, Rello J. Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33(3):272–283
   PubMed Web of Science ®Google Scholar
• . Fine MJ, Auble TE, Yealy DM, . A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997;336(4):243–250
   PubMed Web of Science ®Google Scholar
• . Chalmers JD, Singanayagam A, Akram A, . Severity assessment tools for predicting mortality in hospitalized patients with community-acquired pneumonia. Systemic review and meta-analysis. Thorax. 2010;65(10):878–883
   PubMed Web of Science ®Google Scholar
• . Lim WS, van der Eerden MM, Laing R, . Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382
   PubMed Web of Science ®Google Scholar
• . Choudhury G, Chalmers JD, Mandal P, . Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38(3):643–648
   PubMed Web of Science ®Google Scholar
• . Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123(5):1503–1511
   PubMed Web of Science ®Google Scholar
• . Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta- analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162–1172
   PubMed Web of Science ®Google Scholar
• . Tanaseanu C, Bergallo C, Tegalia O, ; 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61(3):329–338
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration.Drug Safety Communication. Tygacil (tigecycline): Label Change—Increased Mortality Risk. September 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm224626.htm. Accessed September 23, 2013
   Google Scholar
• . Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; 2013
   Google Scholar
• . US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 2013. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm. Accessed September 30, 2013
   Google Scholar
• . Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65(4):713–716
   PubMed Web of Science ®Google Scholar
• . Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(5):1670–1677
   PubMed Web of Science ®Google Scholar
• . Teflaro [prescribing information]. New York, NY: Forest Laboratories, Inc.; 2013
   Google Scholar
• . Low DE, File TM Jr, Eckburg PB, ; FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66( suppl 3): iii33–iii44
   PubMed Web of Science ®Google Scholar
• . File TM Jr, Low DE, Eckburg PE, . Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–1405
   PubMed Web of Science ®Google Scholar
• . US FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. September 7, 2010. http://www.fda.gov/downloads/advisory-committees/committeesmeetingmaterials/drugs/anti-infectivedrugs-advisorycommittee/ucm224656.pdf. Accessed September 23, 2013
   Google Scholar
• . Eckburg PB, Friedland HD, Llorens L, . Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2012;20(4):254–260
   Google Scholar
• . Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66( suppl 3):iii53–iii59
   PubMed Web of Science ®Google Scholar
• . Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278–1284
   PubMedGoogle Scholar
• . Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med. 2006;119(6):512.e1–512.e7
   Web of Science ®Google Scholar
• . File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:993–1016
   PubMed Web of Science ®Google Scholar
• . Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120(9):783–790
   PubMed Web of Science ®Google Scholar
• . Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or = 65 years with community-acquired pneumonia. Clin Ther. 2005;27(8):1251–1259
   PubMed Web of Science ®Google Scholar
• . el Moussaoui R, de Borgie CA, van den Broek P, . Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355
   PubMed Web of Science ®Google Scholar
• . Oster G, Berger A, Edelsberg J, Weber DJ. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ. 2013;16(6):809–819
   PubMedGoogle Scholar
• . Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47( suppl 1):S3–S13
   PubMed Web of Science ®Google Scholar
• . Avdic E, Cushinotto LA, Hughes AH, . Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54(11):1581–1587
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control. Institute for Healthcare Improvement. Antibiotic Stewardship Driver Diagram and Change Package. July 2012. http://www.cdc.gov/getsmart/healthcare/pdfs/Antibiotic_Stewardship_Change_Package_10_30_12.pdf. Accessed July 3, 2013
   Google Scholar
• . Rohde JM, Jacobsen D, Rosenberg DJ. Role of the hospitalist in antimicrobial stewardship: a review of work completed and description of a multisite collaborative. Clin Ther. 2013;35(6):751–757
   PubMed Web of Science ®Google Scholar
• . Srinivasan A. Three Steps to Antibiotic Stewardship. CDC Expert Commentary. Published 15 Nov 2010. http://www.medscape.com/viewarticle/731784. Accessed July 3, 2013
   Google Scholar
• . Murray C, Shaw A, Lloyd M, . A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother. 2014;69(2)515–518
   PubMed Web of Science ®Google Scholar
• . Menéndez R, Torres A, Zalacaín R, ; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960–965
   PubMed Web of Science ®Google Scholar
• . Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164(5):502–508
   PubMedGoogle Scholar
• . Fein AM. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis. 1999;28(4):726–729
   PubMed Web of Science ®Google Scholar
• . Macfarlane JT, Miller AC, Roderick Smith WH, Morris AH, Rose DH. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, Mycoplasma pneumoniae, and psittacosis. Thorax. 1984;39:28–33
   PubMed Web of Science ®Google Scholar
• . Sialer S, Liapikou A, Torres A. What is the best approach to the nonresponding patient with community-acquired pneumonia? Infect Dis Clin North Am. 2013;27(1):189–203
   PubMed Web of Science ®Google Scholar
• . Ewig S, de Roux A, Bauer T, . Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax. 2004;59(5):421–427
   PubMed Web of Science ®Google Scholar
• . The Joint Commission. Pneumonia National Hospital Inpatient Quality Measures (table). November 2, 2011. http://www.jointcommission.org/assets/1/6/Pneumonia.pdf. Accessed July 18, 2013
   Google Scholar
• . Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169(3):342–347
   PubMed Web of Science ®Google Scholar
• . Metersky ML. Should management of pneumonia be an indicator of quality of care? Clin Chest Med. 2011;32(3):575–589
   PubMed Web of Science ®Google Scholar
• . Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161(15):1837–1842
   PubMedGoogle Scholar
• . Baddour LM, Yu VL, Klugman KP, ; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170(4):440–444
   PubMed Web of Science ®Google Scholar
• . Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999; 159(21):2562–2572
   PubMedGoogle Scholar
• . Martinez JA, Horcajada JP, Almela M, . Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36(4):389–395
   PubMed Web of Science ®Google Scholar
• . Bratzler DW, Nsa W, Houck PM. Performance measures for pneumonia: are they valuable and are process measures adequate? Curr Opin Infect Dis. 2007;20(2):182–189
   PubMed Web of Science ®Google Scholar
• . Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with community-acquired pneumonia? Infect Dis Clin North Am. 2013;27(1):71–86
   PubMed Web of Science ®Google Scholar
• . Jha A, Joynt K, Orav J, Epstein AM. The long-term effect of premier pay for performance on patient outcomes. N Engl J Med. 2012;366(17):1606–1615
   PubMed Web of Science ®Google Scholar
• . Arnold FW, Ramirez JA, McDonald C, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest. 2003;124(1):121–124
   PubMed Web of Science ®Google Scholar
• . Carratalà J, Garcia-Vidal C, Ortega L, . Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172(12):922–928
   PubMedGoogle Scholar
• . Fisher SR, Kuo Y, Graham JE, Ottenbacher KJ, Ostir GV. Early ambulation and length of stay in older adults hospitalized with acute illness. Arch Intern Med. 2010;170(21):1942–1943
   PubMedGoogle Scholar
• . Scheurer DB, Miller JG, Blair DI, Pride PJ, Walker GM, Cawley PJ. Hospitalists and improved cost savings in patients with bacterial pneumonia at a state level. South Med J. 2005;98(6):607–610
   PubMed Web of Science ®Google Scholar
• . Bell CM, Schnipper JL, Auerback AD, . Association of communication between hospital-based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2008;24(3):381–386
   PubMed Web of Science ®Google Scholar
• . Lin CY, Barnato AE, Degenholtz HB. Physician follow-up visits after acute care hospitalization for elderly Medicare beneficiaries discharged to noninstitutional settings. J Am Geriatr Soc. 2011;59(10):1947–1954
   PubMed Web of Science ®Google Scholar
• . The Joint Commission. Centers for Medicare and Medicaid Services. Specifications Manual for National Hospital Inpatient Quality MeasuRes. Discharges 01–01–13 (1Q13) through 12–31–13 (4Q13). CMS Readmission Measures (READM-30-PN). Version 4.2:10–34–10–39. http://www.jointcommission.org/assets/1/6/NHQM_Release_Notes_v4_2b_1.1.2013.pdf. Accessed July 1, 2013
   Google Scholar
• . Capelastegui A, España Yandiola PP, Quintana JM, . Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009;136(4):1079–1085
   PubMed Web of Science ®Google Scholar
• . Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008;46(4):550–556
   PubMed Web of Science ®Google Scholar
• . Dharmarajan K, Hsieh AF, Lin Z, . Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363
   PubMed Web of Science ®Google Scholar
• . Shorr AF, Zilberberg MD, Reichley R, . Readmission following hospitalization for pneumonia: the impact of pneumonia type and it implication for hospitals. Clin Infect Dis. 2013;57(3):362–367
   PubMed Web of Science ®Google Scholar
• . Donzé J, Aujesky D, Williams D, Schnipper JL. Potentially avoidable 30-day hospital readmissions in medical patients. JAMA Intern Med. 2013;173(8):632–638
   PubMed Web of Science ®Google Scholar